Janux Therapeutics (JANX) Competitors $23.45 -0.95 (-3.89%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$23.94 +0.50 (+2.11%) As of 09/19/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JANX vs. RNA, MRUS, CRSP, TGTX, PTCT, MENS, ACLX, PCVX, KRYS, and ARWRShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Avidity Biosciences (RNA), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arcellx (ACLX), Vaxcyte (PCVX), Krystal Biotech (KRYS), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Janux Therapeutics vs. Its Competitors Avidity Biosciences Merus CRISPR Therapeutics TG Therapeutics PTC Therapeutics Jyong Biotech Arcellx Vaxcyte Krystal Biotech Arrowhead Pharmaceuticals Avidity Biosciences (NASDAQ:RNA) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends. Do analysts prefer RNA or JANX? Avidity Biosciences presently has a consensus price target of $68.58, suggesting a potential upside of 67.02%. Janux Therapeutics has a consensus price target of $78.31, suggesting a potential upside of 233.93%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Avidity Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 3.05Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.06 Which has more risk & volatility, RNA or JANX? Avidity Biosciences has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.84, meaning that its stock price is 184% more volatile than the S&P 500. Which has better earnings and valuation, RNA or JANX? Janux Therapeutics has lower revenue, but higher earnings than Avidity Biosciences. Janux Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$10.73M558.37-$322.30M-$3.56-11.53Janux Therapeutics$439K3,210.03-$68.99M-$1.80-13.03 Is RNA or JANX more profitable? Janux Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -4,247.77%. Janux Therapeutics' return on equity of -11.48% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-4,247.77% -33.45% -30.22% Janux Therapeutics N/A -11.48%-11.01% Do insiders and institutionals have more ownership in RNA or JANX? 75.4% of Janux Therapeutics shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by insiders. Comparatively, 8.1% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor RNA or JANX? In the previous week, Avidity Biosciences had 12 more articles in the media than Janux Therapeutics. MarketBeat recorded 22 mentions for Avidity Biosciences and 10 mentions for Janux Therapeutics. Avidity Biosciences' average media sentiment score of 0.83 beat Janux Therapeutics' score of 0.32 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryJanux Therapeutics beats Avidity Biosciences on 12 of the 17 factors compared between the two stocks. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41B$3.13B$5.77B$10.45BDividend YieldN/A2.35%5.61%4.56%P/E Ratio-13.0320.9180.5026.82Price / Sales3,210.03261.41454.8291.40Price / CashN/A46.4637.6661.43Price / Book1.209.6015.756.39Net Income-$68.99M-$53.22M$3.30B$271.80M7 Day Performance-2.49%3.11%5.35%3.51%1 Month Performance-2.29%6.23%7.28%9.58%1 Year Performance-53.29%11.02%80.79%28.53% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics2.5746 of 5 stars$23.45-3.9%$78.31+233.9%-53.3%$1.41B$439K-13.0330Analyst ForecastHigh Trading VolumeRNAAvidity Biosciences2.0886 of 5 stars$40.22-10.1%$68.94+71.4%-7.7%$5.76B$10.90M-11.30190Trending NewsAnalyst ForecastAnalyst RevisionMRUSMerus2.8687 of 5 stars$68.09-2.1%$88.75+30.3%+37.3%$5.26B$36.13M-12.3837News CoveragePositive NewsAnalyst ForecastCRSPCRISPR Therapeutics2.9452 of 5 stars$57.84+2.8%$71.60+23.8%+29.3%$5.12B$37.31M-10.65460News CoverageAnalyst ForecastTGTXTG Therapeutics4.2818 of 5 stars$31.75-1.3%$46.25+45.7%+31.3%$5.10B$454.07M85.81290Trending NewsAnalyst ForecastAnalyst RevisionPTCTPTC Therapeutics3.7739 of 5 stars$58.98-3.5%$69.00+17.0%+65.1%$4.85B$806.78M8.461,410Insider TradeMENSJyong BiotechN/A$51.82-15.7%N/AN/A$4.68BN/A0.0031News CoverageHigh Trading VolumeACLXArcellx2.2982 of 5 stars$75.20-1.3%$114.31+52.0%-10.1%$4.23B$107.94M-21.9980Positive NewsInsider TradePCVXVaxcyte2.0157 of 5 stars$31.00-3.6%$106.25+242.7%-72.4%$4.18BN/A-7.54160Positive NewsKRYSKrystal Biotech4.9552 of 5 stars$155.71+8.4%$209.00+34.2%-11.2%$4.16B$359.21M31.65210High Trading VolumeARWRArrowhead Pharmaceuticals4.2164 of 5 stars$28.67-3.5%$43.14+50.5%+47.5%$4.11B$3.55M-22.40400Insider TradeAnalyst Revision Related Companies and Tools Related Companies RNA Competitors MRUS Competitors CRSP Competitors TGTX Competitors PTCT Competitors MENS Competitors ACLX Competitors PCVX Competitors KRYS Competitors ARWR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JANX) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
